148 related articles for article (PubMed ID: 24948512)
1. SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
Tahrani AA
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):678-9. PubMed ID: 24948512
[No Abstract] [Full Text] [Related]
2. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Drug Saf; 2018 Aug; 17(8):837-848. PubMed ID: 30068236
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin/metformin (Synjardy) for type 2 diabetes.
Med Lett Drugs Ther; 2015 Dec; 57(1484):172-4. PubMed ID: 26670554
[No Abstract] [Full Text] [Related]
4. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
[No Abstract] [Full Text] [Related]
5. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
[TBL] [Abstract][Full Text] [Related]
6. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
Davidson JA; Sloan L
Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
Hu J; Zou P; Zhang S; Zhou M; Tan X
Expert Opin Pharmacother; 2016 Dec; 17(18):2471-2477. PubMed ID: 27819159
[TBL] [Abstract][Full Text] [Related]
8. [New fixed combination in type 2 diabetes].
Red
MMW Fortschr Med; 2016 Apr; 158(7):74. PubMed ID: 27071602
[No Abstract] [Full Text] [Related]
9. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Mazidi M; Rezaie P; Gao HK; Kengne AP
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozine (Farxiga) for type 2 diabetes.
Med Lett Drugs Ther; 2014 Feb; 56(1436):13-5. PubMed ID: 24663030
[No Abstract] [Full Text] [Related]
11. Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Bloomgarden Z
J Diabetes; 2013 Sep; 5(3):225-7. PubMed ID: 23714218
[No Abstract] [Full Text] [Related]
12. Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
Wan Seman WJ; Kori N; Rajoo S; Othman H; Mohd Noor N; Wahab NA; Sukor N; Mustafa N; Kamaruddin NA
Diabetes Obes Metab; 2016 Jun; 18(6):628-32. PubMed ID: 26889911
[TBL] [Abstract][Full Text] [Related]
13. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
Bloch MJ
J Am Soc Hypertens; 2016 Mar; 10(3):186-7. PubMed ID: 27408945
[No Abstract] [Full Text] [Related]
15. Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Jabbour SA; Frías JP; Guja C; Hardy E; Ahmed A; Öhman P
Diabetes Obes Metab; 2018 Jun; 20(6):1515-1519. PubMed ID: 29316164
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
[TBL] [Abstract][Full Text] [Related]
17. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Rosenstock J; Aggarwal N; Polidori D; Zhao Y; Arbit D; Usiskin K; Capuano G; Canovatchel W;
Diabetes Care; 2012 Jun; 35(6):1232-8. PubMed ID: 22492586
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin: A Review in Type 2 Diabetes.
Dhillon S
Drugs; 2019 Jul; 79(10):1135-1146. PubMed ID: 31236801
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
Monami M; Nardini C; Mannucci E
Diabetes Obes Metab; 2014 May; 16(5):457-66. PubMed ID: 24320621
[TBL] [Abstract][Full Text] [Related]
20. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
